CY1105424T1 - Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdept - Google Patents
Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdeptInfo
- Publication number
- CY1105424T1 CY1105424T1 CY20061100305T CY061100305T CY1105424T1 CY 1105424 T1 CY1105424 T1 CY 1105424T1 CY 20061100305 T CY20061100305 T CY 20061100305T CY 061100305 T CY061100305 T CY 061100305T CY 1105424 T1 CY1105424 T1 CY 1105424T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nqo2
- prodrug
- fragment
- fusion
- variant
- Prior art date
Links
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 title 1
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 title 1
- 102100022353 Ribosyldihydronicotinamide dehydrogenase [quinone] Human genes 0.000 abstract 10
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 101710131813 Ribosyldihydronicotinamide dehydrogenase [quinone] Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 235000020956 nicotinamide riboside Nutrition 0.000 abstract 1
- 239000011618 nicotinamide riboside Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Electrotherapy Devices (AREA)
- Percussion Or Vibration Massage (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712370.7A GB9712370D0 (en) | 1997-06-14 | 1997-06-14 | Therapeutic systems |
| PCT/GB1998/001731 WO1998057662A2 (en) | 1997-06-14 | 1998-06-15 | Therapeutic systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105424T1 true CY1105424T1 (el) | 2010-04-28 |
Family
ID=10814135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100305T CY1105424T1 (el) | 1997-06-14 | 2006-03-07 | Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdept |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6867231B1 (OSRAM) |
| EP (2) | EP1468698A3 (OSRAM) |
| JP (1) | JP4272263B2 (OSRAM) |
| AT (1) | ATE311905T1 (OSRAM) |
| CA (1) | CA2292608A1 (OSRAM) |
| CY (1) | CY1105424T1 (OSRAM) |
| DE (1) | DE69832702T2 (OSRAM) |
| DK (1) | DK0988059T3 (OSRAM) |
| ES (1) | ES2257810T3 (OSRAM) |
| GB (2) | GB9712370D0 (OSRAM) |
| HK (1) | HK1041824B (OSRAM) |
| WO (1) | WO1998057662A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| GB9903019D0 (en) * | 1999-02-10 | 1999-03-31 | Microbiological Res Authority | Nitroreductase enzymes |
| EP1210358A4 (en) * | 1999-08-13 | 2005-01-05 | Univ Brandeis | PROOF OF NUCLEIC ACIDS |
| CN1315529A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸 |
| EP1432815A4 (en) * | 2001-09-14 | 2006-02-22 | Univ Duke | QUINONE REDUCTASE 2 AND ALDEHYDE DESHYDROGENASE USED AS THERAPEUTIC TARGETS |
| GB0328314D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Bath | Therapeutics |
| US8114626B2 (en) * | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| CA2555675A1 (en) * | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| UA88008C2 (en) | 2004-04-09 | 2009-09-10 | Чугей Сейяку Кабусики Кайся | Water-soluble prodrugs |
| EP1877054A2 (en) * | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
| GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| GB2442202A (en) | 2006-09-30 | 2008-04-02 | Morvus Technology Ltd | Vermin poison |
| WO2016014927A2 (en) | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| KR102629310B1 (ko) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| US10280190B2 (en) * | 2015-03-16 | 2019-05-07 | Chromadex, Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions |
| WO2017011788A1 (en) | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| CN110662542B (zh) | 2016-11-11 | 2025-04-08 | 英国贝尔法斯特女王大学 | 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成 |
| US11633421B2 (en) | 2016-11-29 | 2023-04-25 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US440859A (en) * | 1890-11-18 | Wire-rope machine | ||
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| JPS5460386A (en) * | 1977-10-20 | 1979-05-15 | Fuji Photo Film Co Ltd | Photopolymerizable composition |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DK171727B1 (da) | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| JPS60184252A (ja) * | 1984-03-02 | 1985-09-19 | Canon Inc | 電子写真感光体 |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| NZ225599A (en) | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| AU633020B2 (en) | 1988-07-23 | 1993-01-21 | Novozymes Delta Limited | New secretory leader sequences |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| GB8929097D0 (en) | 1989-12-22 | 1990-02-28 | Imp Cancer Res Tech | Mucin nucleotides |
| GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
| US5633158A (en) * | 1991-10-23 | 1997-05-27 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
| GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
| GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
| GB9323008D0 (en) | 1993-11-05 | 1994-01-05 | Connors Thomas | Improvements relating to cancer therapy |
| GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| GB9524942D0 (en) | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
| WO1997024143A1 (en) * | 1995-12-29 | 1997-07-10 | Aepact Limited | Cytotoxic agents |
| AU5065198A (en) | 1996-11-15 | 1998-06-10 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
-
1997
- 1997-06-14 GB GBGB9712370.7A patent/GB9712370D0/en active Pending
-
1998
- 1998-06-15 EP EP04076964A patent/EP1468698A3/en not_active Withdrawn
- 1998-06-15 ES ES98929555T patent/ES2257810T3/es not_active Expired - Lifetime
- 1998-06-15 DK DK98929555T patent/DK0988059T3/da active
- 1998-06-15 US US09/445,865 patent/US6867231B1/en not_active Expired - Fee Related
- 1998-06-15 CA CA002292608A patent/CA2292608A1/en not_active Abandoned
- 1998-06-15 EP EP98929555A patent/EP0988059B8/en not_active Expired - Lifetime
- 1998-06-15 DE DE69832702T patent/DE69832702T2/de not_active Expired - Fee Related
- 1998-06-15 JP JP50395399A patent/JP4272263B2/ja not_active Expired - Fee Related
- 1998-06-15 WO PCT/GB1998/001731 patent/WO1998057662A2/en not_active Ceased
- 1998-06-15 GB GB9928237A patent/GB2341605B/en not_active Expired - Fee Related
- 1998-06-15 AT AT98929555T patent/ATE311905T1/de not_active IP Right Cessation
-
2000
- 2000-04-13 HK HK02103701.2A patent/HK1041824B/zh not_active IP Right Cessation
-
2002
- 2002-03-13 US US10/099,830 patent/US7138122B2/en not_active Expired - Fee Related
-
2006
- 2006-03-07 CY CY20061100305T patent/CY1105424T1/el unknown
- 2006-11-09 US US11/558,042 patent/US20070166296A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB2341605A (en) | 2000-03-22 |
| HK1041824A1 (en) | 2002-07-26 |
| ATE311905T1 (de) | 2005-12-15 |
| GB9712370D0 (en) | 1997-08-13 |
| US7138122B2 (en) | 2006-11-21 |
| GB9928237D0 (en) | 2000-01-26 |
| JP2002511754A (ja) | 2002-04-16 |
| EP0988059A2 (en) | 2000-03-29 |
| GB2341605B (en) | 2002-02-20 |
| DE69832702T2 (de) | 2006-08-10 |
| HK1041824B (zh) | 2002-11-15 |
| WO1998057662A3 (en) | 1999-08-12 |
| EP1468698A2 (en) | 2004-10-20 |
| EP1468698A3 (en) | 2005-03-23 |
| DK0988059T3 (da) | 2006-01-23 |
| DE69832702D1 (de) | 2006-01-12 |
| ES2257810T3 (es) | 2006-08-01 |
| WO1998057662A2 (en) | 1998-12-23 |
| US20070166296A1 (en) | 2007-07-19 |
| JP4272263B2 (ja) | 2009-06-03 |
| HK1023069A1 (en) | 2000-09-01 |
| CA2292608A1 (en) | 1998-12-23 |
| EP0988059B8 (en) | 2006-03-01 |
| US20030086933A1 (en) | 2003-05-08 |
| GB2341605A8 (en) | 2000-03-28 |
| EP0988059B1 (en) | 2005-12-07 |
| US6867231B1 (en) | 2005-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2341605A (en) | Therapeutic systems | |
| ATE93236T1 (de) | Acylatiertes uridin und cytidin und deren verwendungen. | |
| CY1106798T1 (el) | Ανθρωπινα μεσεγχυματικα βλαστοκυτταρα απο περιφερειακο αιμα | |
| TR199700574T1 (xx) | Molek�ler �aperon �retiminin haz�rlanmas� i�in yararl� hidroksilamin t�revleri ve bu t�revlerin haz�rlanmas�. | |
| HN1998000143A (es) | Tetrahidronaftalenos substituidos y compuestos analogos. | |
| SG81890A1 (en) | Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity | |
| KR900701827A (ko) | 치료용 펩타이드 | |
| ES2095772T3 (es) | Utilizacion de derivados de rifamicina para producir un medicamento destinado al tratamiento de la toxoplasmosis. | |
| DK0527757T3 (da) | Sammensætning og fremgangsmåde til behandling af akne vulgaris og forsinkelse af ældning | |
| NO20000576L (no) | Blanding og fremgangsmåte for regulering av celleproliferasjon og celledød | |
| DK0817646T3 (da) | Fremgangsmåder til behandling af inflammation og præparater derfor | |
| PT1212428E (pt) | Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores | |
| ES2043610T3 (es) | Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno. | |
| BR9916460A (pt) | Produção de ácido ascórbico usando levedura | |
| NL350033I2 (nl) | Gefuseerde middelen voor biologische controle | |
| ATE222914T1 (de) | Diester-derivate von acyclovir | |
| EA199801007A1 (ru) | Способ биосинтеза, позволяющий получать кобаламины | |
| ES2066422T3 (es) | Expresion de un arn multigenes con actividad de autoempalme. | |
| NO980275D0 (no) | Dobbelt virusinaktivert humant blodplasma, blodplasmaderivater fremstilt derav og fremgangsmåte for deres fremstilling | |
| ATE499115T1 (de) | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase | |
| RU2000106057A (ru) | Применение никотинамидадениндинуклеотида и его аналогов для лечения злокачественных и инфекционных заболеваний | |
| AR009470A1 (es) | COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS. | |
| Yoo et al. | Identification of Ser-543 as the major regulatory phosphorylation site in spinach leaf nitrate reductase | |
| GT199300023A (es) | Derivados de aminoacidos | |
| GT199200002A (es) | Derivados de aminoacidos |